Hematologic Oncologist
Conditions Treated:
About Me
I am a board-certified hematologist and medical oncologist, and my clinical expertise includes using stem cell transplantation to treat blood cancers, particularly lymphoma and chronic lymphocytic leukemia. I work as part of a multidisciplinary team of transplantation specialists who treat patients with these diseases. My research program includes finding methods to identify lymphoma patients who will benefit most from either autologous or allogeneic stem cell transplantation and developing new transplantation approaches to improve patients’ outcomes. In particular, I’m involved in studies that are introducing novel drugs with activity against lymphoma into transplantation programs, and developing new ways to deliver cellular therapy through transplantation.
- Clinical Expertise: Hematologic Malignancies; Stem Cell Transplantation
- Languages Spoken: English
- Education: MD, Case Western Reserve School of Medicine
- Residencies: University of Michigan Medical Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Hematology; Medical Oncology
See My Colleagues
Publications
Visit PubMed for a full listing of Craig S. Sauter’s journal articles
Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.Clinical Trials
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Craig S. Sauter
- A Phase I Study of Ibrutinib plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
- A Phase II Study Assessing the Impact of Stem Cell Dose on Progression-Free Survival in Patients Receiving High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Recurrent or Persistent Diffuse Large B-Cell Lymphoma
Clinical Trials Co-Investigated by Craig S. Sauter
- A Phase I Study of Genetically Modified T Cells to Treat Recurrent or Refractory Chronic Lymphocytic Leukemia
- A Phase I Study of Immunotherapy with Genetically Engineered T Cells (CAR T Cells) for Advanced Breast Cancer
- A Phase I Study of Modified T Cells Targeted to CD19-Positive Acute Lymphoblastic Leukemia Relapsing After Allogeneic Stem Cell Transplantation
- A Phase I Trial of B-Cell Acute Lymphoblastic Leukemia Treated with Immunotherapy Using Autologous T Cells Gene-Targeted to the B-Cell Antigen CD19
- A Phase II Study Evaluating the Use of Donated EBV-Immune T Cells to Treat Transplant Recipients with EBV
- A Phase II Study of Immunotherapy with Genetically Modified T Cells (JCAR015 Cells) to Treat Recurrent or Persistent B-Cell Acute Lymphoblastic Leukemia: The ROCKET Study
- A Study of EBV Cytotoxic T Lymphocytes to Treat EBV Lymphoma and Lymphoproliferative Disorders
Insurance
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.
Learn more